CSF positive group
| Case | Age/sex | Site | HCG serum/CSF (mIU/ml) | HCG-β serum/CSF (ng/ml) | Initial treatment | Recurrence | Treatment at recurrence | Latest follow up |
|---|---|---|---|---|---|---|---|---|
| 8 | 25/M | S | <0.1/1.0 | 0.28/0.56 | R | — | — | 8 years/alive |
| 9 | 22/M | S | 1.2/3.3 | 0.34/0.24 | R | — | — | 6 years/alive |
| 10 | 19/M | P | <0.1/1.3 | <0.1/<0.1 | R | — | — | 3 years/alive |
| 11 | 18/M | P | -/- | 0.19/0.4 | R | 6 months; spinal; normal serum HCG-β, CSF HCG-β (+) | Spinal irradication chemotherapy | 8 years/died glioblastoma |
| 8 months; intraperitoneal; raised serum HCG-β | ||||||||
| 12 | 47/M | P | 2.0/2.0 | <0.1/0.86 | R | 24 months; spinal | Chemotherapy | 6 years/alive |
Abbreviations as in footnote of table 1.